Autophagy inhibition augments the anticancer effects of epirubicin treatment in...
-
Upload
miles-cummings -
Category
Documents
-
view
216 -
download
2
Transcript of Autophagy inhibition augments the anticancer effects of epirubicin treatment in...
![Page 1: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/1.jpg)
Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and
-resistant triple-negative breast cancer
IMI CONFIDENTIAL
Clinical Cancer Research, Published OnlineFirst April 10, 2014, IF=8.193
古春博2014.12.15
![Page 2: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/2.jpg)
www.xianimi.com 2IMI CONFIDENTIAL
Introduction
Triple-negative breast cancer (TNBC) was coined in 2005 for cancers lacking
detectable expression of estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2/NEU/ERBB2).
Patients with TNBC have poorer outcomes due to drug resistance and more
aggressive recurrent disease compared with other subtypes.
Autophagy has a cytoprotective function that enables cancer cells to cope with
cytotoxic or other stresses induced by treatment. Thus, anticancer therapies
commonly lead to the upregulation of autophagy.
![Page 3: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/3.jpg)
• FDA-approved chloroquine or hydroxychloroquine in combination with chemo- or radiotherapy for the treatment of different cancers, including breast, colon, brain, prostate, and non–small cell lung cancers, are currently under way.
• In this study, we show that epirubicin induced autophagic flux in TNBC cell lines.We developed anthracycline-resistant TNBC cell lines and demonstrate that in the absence of treatment , they exhibit relatively high levels of autophagic flux, compared with their parental cell lines.
• We provide evidence supporting the effective combination of epirubicin with pharmacologic (chloroquine and hydroxychloroquine) or genetic (siRNA) inhibition of autophagy, both in TNBC parental cell lines and their derivative anthracycline-resistant lines, in vitro and in xenograft mouse models.
![Page 4: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/4.jpg)
Figure 1. Epirubicin treatment reduces cell viability and increases autophagic flux in TNBC cells
![Page 5: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/5.jpg)
Figure 2 TNBC cells resistant to epirubicin have higher levels of autophagic flux relative to parent cells.
![Page 6: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/6.jpg)
Figure 3. Combination treatment of autophagy inhibition and epirubicin enhances the loss in cell viability.
![Page 7: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/7.jpg)
Figure 4. Autophagy inhibition reduces viability and augments cell death of TNBC lines resistant to epirubicin.
![Page 8: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/8.jpg)
Figure 5. Assessment of in vivoautophagy-related protein levelsin MDA-MB-231 xenograft tumors.
![Page 9: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/9.jpg)
Figure 6. Combinatorial epirubicin (EPI) and hydroxychloroquine (HCQ) treatment reduces growth in MDA-MB-231 and MDA-MB-231-R8 tumor xenograft models.
![Page 10: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/10.jpg)
www.xianimi.comIMI CONFIDENTIAL 10
Thank you!
![Page 11: Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer IMI.](https://reader034.fdocuments.us/reader034/viewer/2022051516/56649ef45503460f94c0779d/html5/thumbnails/11.jpg)
www.xianimi.com
投稿案例分析
IMI CONFIDENTIAL 11
以前的稿件,只投一个杂志,经过 1-3个月后,很多拒稿现象。之后由于忙于手头的工作,又在延迟了投稿过程,导致稿件堆积。解决办法:①、将所有 SCI补充投稿杂志至 3个;②、每月给主管发送两次投稿记录,由主管监督。